Equity Overview
Price & Market Data
Price: $2.44
Daily Change: -$0.015 / 0.61%
Daily Range: $2.43 - $2.72
Market Cap: $47,978,364
Daily Volume: 101,573
Performance Metrics
1 Week: -8.55%
1 Month: -26.79%
3 Months: 24.87%
6 Months: -13.38%
1 Year: 22.39%
YTD: 11.82%
Details
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.